Alkermes reported dose-dependent reductions in ADHD symptom scores with investigational ALKS 7290 in a 14-day Phase 1b trial of 50 adults; median declines from baseline were 14 points at 20 mg and 19 at 50 mg. The drug was generally well tolerated.
Participants completed a two-week washout of prior medications before receiving daily split doses of 20 mg or 50 mg of ALKS 7290, or placebo, during inpatient treatment. On the Adult ADHD Investigator Symptom Rating Scale, improvements appeared by day 6 across inattention and hyperactivity symptoms. Median severity scores also fell by 1 point at 20 mg and 2 points at 50 mg, shifting ratings from markedly or moderately ill to mildly ill.
No serious treatment-emergent adverse events were reported. Common, mild adverse events included insomnia, frequent urination, dizziness, altered sustained attention, urinary urgency and constipation. No participant taking ALKS 7290 discontinued, while two placebo participants did. Alkermes is enrolling about 312 adults for a four-week Phase 2 study; the first participant was dosed in September 2026.
